ATE254472T1 - Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält - Google Patents

Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Info

Publication number
ATE254472T1
ATE254472T1 AT97907445T AT97907445T ATE254472T1 AT E254472 T1 ATE254472 T1 AT E254472T1 AT 97907445 T AT97907445 T AT 97907445T AT 97907445 T AT97907445 T AT 97907445T AT E254472 T1 ATE254472 T1 AT E254472T1
Authority
AT
Austria
Prior art keywords
tfpi
inhibitor
tissue factor
containing tissue
vascular formation
Prior art date
Application number
AT97907445T
Other languages
English (en)
Inventor
Tsutornu Hamuro
Yo Nakahara
Sumiyo Takemoto
Seiji Miyamoto
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE254472T1 publication Critical patent/ATE254472T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT97907445T 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält ATE254472T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9617696 1996-03-25
PCT/JP1997/000973 WO1997035609A1 (fr) 1996-03-25 1997-03-24 Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire

Publications (1)

Publication Number Publication Date
ATE254472T1 true ATE254472T1 (de) 2003-12-15

Family

ID=14158025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907445T ATE254472T1 (de) 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Country Status (9)

Country Link
US (1) US6060449A (de)
EP (1) EP0914830B1 (de)
JP (1) JP4129994B2 (de)
KR (1) KR100442758B1 (de)
AT (1) ATE254472T1 (de)
AU (1) AU706582B2 (de)
CA (1) CA2250008A1 (de)
DE (1) DE69726281T2 (de)
WO (1) WO1997035609A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1226245A (zh) 1996-06-20 1999-08-18 德克萨斯州大学系统董事会 具有药理活性的化合物,其制备方法及其用途
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
JP2004511219A (ja) 2000-07-12 2004-04-15 アジェンシス，インコーポレイテッド 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CA2652926A1 (en) 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2010514692A (ja) 2006-12-20 2010-05-06 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
US8772238B2 (en) * 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
WO2011130728A1 (en) 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
JP3428687B2 (ja) * 1993-06-30 2003-07-22 財団法人化学及血清療法研究所 組織因子凝固系インヒビターの調製法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
AU1944997A (en) 1997-10-17
CA2250008A1 (en) 1997-10-02
KR19990087825A (ko) 1999-12-27
US6060449A (en) 2000-05-09
DE69726281D1 (de) 2003-12-24
AU706582B2 (en) 1999-06-17
JP4129994B2 (ja) 2008-08-06
EP0914830B1 (de) 2003-11-19
WO1997035609A1 (fr) 1997-10-02
DE69726281T2 (de) 2004-08-26
KR100442758B1 (ko) 2004-10-06
EP0914830A1 (de) 1999-05-12
EP0914830A4 (de) 2002-03-20

Similar Documents

Publication Publication Date Title
SE8503680D0 (sv) Indolderivat
EA199800268A1 (ru) Замещенные имидазолы, обладающие антиканцерогенной и цитокин-ингибирующей активностью
EP0906307A4 (de) Substituierte imidazole mit cytokinin-inhibirender wirkung
TNSN94105A1 (fr) Composes sulfonamides tricycliques utiles pour l'inhibition de la fonction proteine g et pour le traitement des maladies proliferatives
DK0950100T3 (da) Keratinocytvækstfaktor-2- (KGF-2- eller fibroblastvækstfaktor-12-, FGF-12-) mutanter
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
DE3774918D1 (de) Cancerostatisches mittel.
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE254472T1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
ATE79031T1 (de) Verwendung von ketonderivaten zur behandlung von depressionen.
DE69720542D1 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
FI951858A0 (fi) Kinoloni- ja akridonijohdannaisia virtsanpidätyskyvyttömyyden hoidossa
DE69127976D1 (de) Tropolonderivate und pharmazeutische zubereitungen davon zur vorbeugung und behandlung von ischämischen krankheiten
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
TW325472B (en) A pharmaceutical composition for preventing cancer comprising 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.
NO903585L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksaziner.
SE9902596D0 (sv) Pharmaceutically active compounds
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties